1 / 4

ENHANCE Trial Results: Impact on Adverse Events, LDL Values, and CV Events

This article provides the trial results of the ENHANCE study conducted by Merck/Schering-Plough Pharmaceuticals on the impact of a particular treatment on adverse events, LDL values, and cardiovascular events. The study was conducted on January 14, 2008.

merrillm
Download Presentation

ENHANCE Trial Results: Impact on Adverse Events, LDL Values, and CV Events

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ENHANCE: Primary end point Merck/Schering-Plough PharmaceuticalsENHANCE trial results. January 14, 2008

  2. ENHANCE: Adverse events Merck/Schering-Plough PharmaceuticalsENHANCE trial results. January 14, 2008

  3. ENHANCE: LDL values at baseline and % reduction after treatment Merck/Schering-Plough PharmaceuticalsENHANCE trial results. January 14, 2008

  4. ENHANCE: CV events Merck/Schering-Plough PharmaceuticalsENHANCE trial results. January 14, 2008

More Related